YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for...
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7...
ALACHUA, Fla., December 17, 2024 – RTI Surgical ("the Company"), a leading CDMO pushing the boundaries of innovation and tissue...
Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD),...
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis...
Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical...
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with...
SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the “Company” or “AMS”), a...
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed...
WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology...
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global leader in cellular and cell-derived therapeutics for the...
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting...
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
As of December 16, 2024, the Company has repurchased a total of 102,405 shares at an average price of $1.9869...
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver,...
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Borussia Dortmund (FSE: BVB) Borussia Dortmund is...
Momentum Building with Novel Cardiology AI SolutionMINNETONKA, Minn.--(BUSINESS WIRE)--#CVD--AngioInsight, Inc., an innovator in medical imaging technologies, is pleased to announce...
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway...